Pimobendan Increases Survival of Cardiomyopathic Hamsters

SummaryWe investigated the effect of the new cardiotonic drug pimobendan on survival of hereditary cardiomyopathic hamsters. Untreated cardiomyopathic hamsters served as controls. A 50% mortality was observed after 280 days for the control group and after 318 days for the pimobendan-treated animals....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cardiovascular pharmacology 1989-03, Vol.13 (3), p.508-508
Hauptverfasser:	van Meel, Jacques C. A, Mauz, Annerose B. M, Wienen, Wolfgang, Diederen, Willi
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cardiomyopathies - drug therapy Cardiomyopathies - mortality Cardiotonic Agents - therapeutic use Cricetinae Male Pyridazines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	SummaryWe investigated the effect of the new cardiotonic drug pimobendan on survival of hereditary cardiomyopathic hamsters. Untreated cardiomyopathic hamsters served as controls. A 50% mortality was observed after 280 days for the control group and after 318 days for the pimobendan-treated animals. After 340 days, survival was 0% for the untreated cardiomyopathic hamsters and 27% in the pimobendan-treated group. We conclude that pimobendan slows the progression of heart failure in cardiomyopathic hamsters.
ISSN:	0160-2446 1533-4023
DOI:	10.1097/00005344-198903000-00021